Citalopram hydrobromide (Synonyms:(±-Citalopram hydrobromide; Lu 10-171))
目录号 : KM18242 CAS No. : 59729-32-7 纯度 : 98%

Citalopram hydrobromide 是一种选择性血清素再摄取抑制剂 (SSRI)。 Citalopram hydrobromide 抑制 5-HT 摄取进入突触体,IC50 为 1.8 nM。 Citalopram hydrobromide 抑制兔血小板中 5-HT 的摄取,IC50 为 14 nM。具有抗抑郁作用。

规格 价格 是否有货 数量
10mg
In-stock
50mg
In-stock
100mg
In-stock
200mg 询价 In-stock
500mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC50 of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC50 of 14 nM. Antidepressant effect.

体外研究

Citalopram(25-150 μM) shows a concentration-dependent cytotoxicity on the viability of rat B104, human SH-SY5Y, IMR32 and Kelly neuroblastoma cell lines and human primary Schwann cells (HSC).

Cell Viability Assay

Cell Line: Rat B104, human SH-SY5Y, IMR32 and Kelly neuroblastoma cells
Concentration: 50, 100, 125, 150 μM for B104 cells
25, 50, 100, 125 μM for SH-SY5Y cells
25, 50, 100, 125, 150 μM for Kelly cells
25, 50, 100, 125 μM for IMR32 cells
50, 100, 125, 150 μM for HSCs
Incubation Time: 24 h ours
Result: Significantly decreased B104 cell viability, 61%, 33% and 11% at respectively 100, 125 and 150 μM in B104 cell line.
Drastically decreased SH-SY5Y cell viability, 17%, 1% at respectively 100 and 125 μM in SH-SY5Y cell line.
Significantly decreased Kelly cell viability, 64%, 9% and 0% at respectively 100, 125 and 150 μM in Kelly cell line.
Drastically decreased IMR32 cell viability, 36%, 1% and 0% at respectively 50, 100 and 125 μM in IMR32 cell line.
体内研究

Acute administration of Citalopram (1-10 mg/kg, i.p. 1 h before an elevated plus-maze test) to Spontaneously Hypertensive rats (SHRs), Lewis (LEW) rats, and Wistar-Kyoto (WKY) rats, i.e., rat strains differing for their emotionality, promotes anxiety, and/or hypoactivity, except in WKY rats. In the three strains, such a pretreatment increased central 5-HT levels and/or decreased 5-hydroxyindoleacetic acid levels.

Animal Model: Male rats from the SHR, LEW, and WKY strains, aged 6–8 weeks
Dosage: 1, 3.3, or 10 mg/kg
Administration: Injected i.p.
Result: Increased significantly 5-HT in SHRs and WKY rats, and decreased 5-HIAA in all strains, in either a dose-dependent (LEW and WKY rats) or a dose-independent (SHRs) manner.
分子式
C20H22BrFN2O
分子量
405.30
CAS号
59729-32-7
中文名称
氢溴酸西酞普兰;氢溴酸西酞;西酞普兰氢溴酸盐
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 38 mg/mL (93.76 mM)

H2O : 10 mg/mL (24.67 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4673 mL 12.3365 mL 24.6731 mL
5 mM 0.4935 mL 2.4673 mL 4.9346 mL
10 mM 0.2467 mL 1.2337 mL 2.4673 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 110 mg/mL (271.40 mM); Clear solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.17 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.17 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

临床试验
科研文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号